# US 2026/0033466 A1 · Method and animal model for inducing bcc tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0033466 A1
- Document ID: US20260033466A1
- Status: Published application
- Kind: A1
- Application number: 19/106,825
- Filed: 2023-08-30
- Published: 2026-02-05
- Earliest claimed: 2022-08-30
- Assignees: Feldan Bio Inc.
- Applicants: Feldan Bio Inc.
- Inventors: Nancy MESSIER; Frederic COUTURE
- Web page: https://patentgrep.com/patent/US20260033466A1

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- G01N 33/5017: {for testing neoplastic activity}
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 35/00: Antineoplastic agents
- C07K 14/4746: {p53}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/5088: {of vertebrates}
- G01N 33/5751: of the skin, e.g. melanoma
- A01K 2217/054: inducing loss of function
- A01K 2217/058: due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2217/203: Animal model comprising inducible/conditional expression system, e.g. hormones, tet
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Methods for inducing basal cell carcinoma (BCC) or BCC tumors, as well as an inducible non-human animal models of BCC, are defined herein. The methods and animal models comprise targeting Ptch1 and/or a tumor suppressor gene via conditional expression of one or more short hairpin RNAs (shRNAs) in the skin of said animals.

## Claims

### Claim 1

A genetically-modified non-human animal whose genome comprises one or more sequences encoding a short hairpin RNA (shRNA) targeting Ptch1, and a shRNA targeting p53 or other tumor suppressor genes, wherein expression or co-expression of said shRNAs is inducible and in the skin of said non-human animal.

### Claim 2

A genetically-modified non-human animal whose genome comprises:
an inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53;
and
a gene encoding a site-specific recombinase that cleaves the upstream cleavable sequence, wherein said gene is under the control of a skin cell-specific promoter and wherein expression of said gene is inducible.

### Claim 3 (depends on 2)

The non-human animal of claim 2, wherein the cassette comprises an inducible promoter which controls the expression of the upstream cleavable sequence, first and second downstream sequences, wherein said inducible promoter is regulated by a transcriptional activator protein.

### Claim 4 (depends on 3)

The non-human animal of claim 3, wherein the genome further comprises a gene encoding the transcriptional activator protein, wherein said gene is inserted into a constitutively expressed gene locus (e.g., ROSA26).

### Claim 5 (depends on 4)

The non-human animal of claim 4, wherein expression of the gene encoding the transcriptional activator protein is inducible.

### Claim 6 (depends on 3, 4, 5)

The non-human animal of any one of claims 3 to 5, wherein said inducible promoter is or comprises a tetracycline-response element (TRE) and wherein said transcriptional activator is a tetracycline transactivator (e.g., rtTA or rtTA2).

### Claim 7 (depends on 3, 4, 5, 6)

The non-human animal of any one of claims 3 to 6, wherein expression of the transcriptional activator is induced in the presence of tetracycline and/or doxycycline.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The non-human animal of any one of claims 2 to 7, wherein said skin cell-specific promoter is or comprises keratin 14 (K14), Krt6a, or K5.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The non-human animal of any one of claims 2 to 8, wherein said upstream cleavable sequence is or comprises a loxP site (i.e., Lox-STOP-Lox site).

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The non-human animal of any one of claims 2 to 9, wherein said upstream cleavable sequence is or comprises a flippase recognition target (FRT) site.

### Claim 11 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10)

The non-human animal of any one of claims 2 to 10, wherein said recombinase is or comprises a Cre recombinase or a flippase recombinase.

### Claim 12 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The non-human animal of any one of claims 2 to 11, wherein said recombinase is fused to a receptor, such as an estrogen receptor (e.g., ERT2).

### Claim 13 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The non-human animal of any one of claims 2 to 12, wherein activation of the recombinase is induced in the presence of tamoxifen.

### Claim 14 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The non-human animal of any one of claims 2 to 13, wherein said cassette further comprises a third downstream gene encoding a fluorescent marker or protein (e.g., green fluorescent protein [GFP]).

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The non-human animal of any one of claims 2 to 14, wherein said genetic safe-harbour site is or comprises the Col1a1 gene locus.

### Claim 16 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The non-human animal of any one of claims 2 to 15, wherein the sequence encoding the short hairpin RNA (shRNA) targeting Ptch1 comprises the sequence of any one of SEQ ID NOs: 1-10.

### Claim 17 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The non-human animal of any one of claims 2 to 16, wherein the sequence encoding the short hairpin RNA (shRNA) targeting p53 comprises the sequence of SEQ ID NO: 11.

### Claim 18 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The non-human animal of any one of claims 2 to 17, wherein said non-human animal is a rodent (e.g., mouse, rat, hamster, or guinea pig), ferret, rabbit, pig, monkey, or primate.

### Claim 19 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The non-human animal of any one of claims 2 to 18, for use as a non-human animal model of inducible basal cell carcinoma (BCC).

### Claim 20

A method of producing an inducible non-human animal, the method comprising:
inserting an inducible cassette into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53;
and
inserting into the genome of the non-human animal an inducible gene encoding a site-specific recombinase that cleaves the upstream cleavable sequence, wherein said gene is under the control of a skin cell-specific promoter.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cassette further comprises an inducible promoter which controls the expression of the upstream cleavable sequence, first and second downstream sequences, wherein said inducible promoter is regulated by a transcriptional activator protein.

### Claim 22 (depends on 21)

The method of claim 21, further comprising inserting into the genome of the non-human animal a gene encoding the transcriptional activator protein, wherein said gene is inserted into a constitutively expressed gene locus (e.g., ROSA26).

### Claim 23 (depends on 22)

The method of claim 22, wherein expression of the gene encoding the transcriptional activator protein is inducible.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claims 21 to 23, wherein said inducible promoter is or comprises a tetracycline-response element (TRE) and wherein said transcriptional activator is a tetracycline transactivator (e.g., rtTA or rtTA2).

### Claim 25 (depends on 21, 22, 23, 24)

The non-human animal of any one of claims 21 to 24, wherein expression of the transcriptional activator is induced in the presence of tetracycline and/or doxycycline.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The method of any one of claims 20 to 25, wherein said skin cell-specific promoter is or comprises keratin 14 (K14), Krt6a, or K5.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 20 to 26, wherein said upstream cleavable sequence is or comprises a loxP site (i.e., Lox-STOP-Lox site).

### Claim 28 (depends on 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 20 to 27, wherein said upstream cleavable sequence is or comprises a flippase recognition target (FRT) site.

### Claim 29 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 20 to 28, wherein said recombinase is or comprises a Cre recombinase or a flippase recombinase.

### Claim 30 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 20 to 29, wherein said recombinase is fused to a receptor, such as an estrogen receptor (e.g., ERT2).

### Claim 31 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 20 to 30, wherein activation of the recombinase is induced in the presence of tamoxifen.

### Claim 32 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 20 to 31, wherein said cassette further comprises a third downstream gene encoding a fluorescent marker or protein (e.g., green fluorescent protein [GFP]).

### Claim 33 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 20 to 32, wherein said genetic safe-harbour site is or comprises the Col1a1 gene locus.

### Claim 34 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 20 to 33, wherein the sequence encoding the short hairpin RNA (shRNA) targeting Ptch1 comprises the sequence of any one of SEQ ID NOs: 1-10.

### Claim 35 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 20 to 34, wherein the sequence encoding the short hairpin RNA (shRNA) targeting p53 comprises the sequence of SEQ ID NO: 11.

### Claim 36 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 20 to 35, wherein said non-human animal is a rodent (e.g., mouse, rat, hamster, or guinea pig), ferret, rabbit, pig, monkey, or primate.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 20 to 36, wherein said non-human animal is the non-human animal as defined in any one of claims 1 to 19.

### Claim 38

A method for inducing basal cell carcinoma (BCC) or BCC tumor(s) in a non-human animal, the method comprising:
providing a non-human animal whose genome comprises:
an inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53;
and
a gene encoding a site-specific recombinase that cleaves the upstream cleavable sequence,
wherein said gene is under the control of a skin cell-specific promoter and wherein expression of said gene is inducible;
and
administering a compound for inducing expression of the recombinase.

### Claim 39 (depends on 38)

The method of claim 38, wherein the cassette further comprises an inducible promoter which controls the expression of the upstream cleavable sequence, first and second downstream sequences, wherein said inducible promoter is regulated by a transcriptional activator protein.

### Claim 40 (depends on 39)

The method of claim 39, wherein the genome of the non-human animal further comprises a gene encoding the transcriptional activator protein, wherein said gene is inserted into a constitutively expressed gene locus (e.g., ROSA26).

### Claim 41 (depends on 40)

The method of claim 40, wherein expression of the gene encoding the transcriptional activator protein is inducible.

### Claim 42 (depends on 39, 40, 41)

The method of any one of claims 39 to 41, wherein said inducible promoter is or comprises a tetracycline-response element (TRE) and wherein said transcriptional activator is a tetracycline transactivator (e.g., rtTA or rtTA2).

### Claim 43 (depends on 39, 40, 41, 42)

The method of any one of claims 39 to 42, further comprising administering a compound for inducing expression of the transcriptional activator protein.

### Claim 44 (depends on 43)

The method of claim 43, wherein the compound for inducing expression of the transcriptional regulator protein is or comprises tetracycline or doxycycline.

### Claim 45 (depends on 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 38 to 44, wherein the compound for inducing activation of the recombinase is or comprises tamoxifen.

### Claim 46 (depends on 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 38 to 45, further comprising exposing the non-human animal to ultraviolet radiation (e.g., UV-B) and/or ionizing radiation.

### Claim 47 (depends on 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 38 to 46, wherein the non-human animal is produced by the method of any one of claims 20 to 37.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 38 to 47, wherein the non-human animal is the non-human animal as defined in any one of claims 1 to 19.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

An isolated cell from the non-human animal as defined in any one of claims 1 to 19 or from a non-human animal produced by the method of any one of claims 20 to 37.

### Claim 50

A cell comprising:
an inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53;
and
a gene encoding a site-specific recombinase that cleaves the upstream cleavable sequence, wherein said gene is under the control of a skin cell-specific promoter and wherein expression of said gene is inducible.

### Claim 51 (depends on 50)

The cell of claim 50, wherein the cassette comprises an inducible promoter which controls the expression of the upstream cleavable sequence, first and second downstream sequences, wherein said inducible promoter is regulated by a transcriptional activator protein.

### Claim 52 (depends on 51)

The cell of claim 51, further comprising a gene encoding the transcriptional activator protein, wherein said gene is inserted into a constitutively expressed gene locus (e.g., ROSA26).

### Claim 53 (depends on 52)

The cell of claim 52, wherein expression of the gene encoding the transcriptional activator protein is inducible.

### Claim 54 (depends on 51, 52, 53)

The cell of any one of claims 51 to 53, wherein said inducible promoter is or comprises a tetracycline-response element (TRE) and wherein said transcriptional activator is a tetracycline transactivator (e.g., rtTA or rtTA2).

### Claim 55 (depends on 51, 52, 53, 54)

The cell of any one of claims 51 to 54, wherein expression of the transcriptional activator is induced in the presence of tetracycline and/or doxycycline.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The cell of any one of claims 50 to 55, wherein said skin cell-specific promoter is or comprises keratin 14 (K14), Krt6a, or K5.

### Claim 57 (depends on 50, 51, 52, 53, 54, 55, 56)

The cell of any one of claims 50 to 56, wherein said upstream cleavable sequence is or comprises a loxP site (i.e., Lox-STOP-Lox site).

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The cell of any one of claims 50 to 57, wherein said upstream cleavable sequence is or comprises a flippase recognition target (FRT) site.

### Claim 59 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58)

The cell of any one of claims 50 to 58, wherein said recombinase is or comprises a Cre recombinase or a flippase recombinase.

### Claim 60 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The cell of any one of claims 50 to 59, wherein said recombinase is fused to a receptor, such as an estrogen receptor (e.g., ERT2).

### Claim 61 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The cell of any one of claims 50 to 60, wherein activation of the recombinase is induced in the presence of tamoxifen.

### Claim 62 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The cell of any one of claims 50 to 61, wherein said cassette further comprises a third downstream gene encoding a fluorescent marker or protein (e.g., green fluorescent protein [GFP]).

### Claim 63 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The cell of any one of claims 50 to 62, wherein said genetic safe-harbour site is or comprises the Col1a1 gene locus.

### Claim 64 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The cell of any one of claims 50 to 63, wherein the sequence encoding the short hairpin RNA (shRNA) targeting Ptch1 comprises the sequence of any one of SEQ ID NOs: 1-10.

### Claim 65 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The cell of any one of claims 50 to 64, wherein the sequence encoding the short hairpin RNA (shRNA) targeting p53 comprises the sequence of SEQ ID NO: 11.

### Claim 66 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The cell of any one of claims 50 to 65, wherein said cell is a mammalian cell.

### Claim 67 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The cell of any one of claims 50 to 66, wherein said cell is from a non-human animal, such as a rodent (e.g., mouse, rat, hamster, or guinea pig), ferret, rabbit, pig, monkey, or primate.

### Claim 68 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The cell of any one of claims 50 to 67, wherein said cell is a skin cell, skin basal cell, germ cell, stem cell, embryonic stem cell, multipotent stem cell, pluripotent stem cell, totipotent stem cells, or a fertilized cell (e.g., oocyte, zygote).

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of evaluating in a non-human animal, a candidate compound or intervention useful in the treatment, reduction or prevention of basal cell carcinoma (BCC) or BCC tumors, the method comprising the steps of:
providing the non-human animal as defined in any one of claims 1 to 19 or a non-human animal produced by the method of any one of claims 20 to 37;
inducing BCC or BCC tumor(s) by the method of any one of claims 38 to 48; and
administering the candidate compound or intervention to the non-human animal.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of the non-human animal as defined in any one of claims 1 to 19 for evaluating a candidate compound or intervention useful in the treatment, reduction or prevention of basal cell carcinoma (BCC) or BCC tumors.

### Claim 71

A gene cassette or vector (e.g., plasmid) comprising:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53.

### Claim 72 (depends on 71)

The gene cassette or plasmid of claim 71, wherein the expression of the cassette or vector is inducible.

### Claim 73

A nucleotide sequence comprising:
a sequence encoding inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53;
and
a sequence encoding a gene encoding a site-specific recombinase that cleaves the upstream cleavable sequence, wherein said gene is under the control of a skin cell-specific promoter and wherein expression of said gene is inducible.

### Claim 74 (depends on 73)

The nucleotide sequence of claim 73, wherein the cassette comprises a sequence encoding an inducible promoter which controls the expression of the upstream cleavable sequence, first and second downstream sequences, wherein said inducible promoter is regulated by a transcriptional activator protein.

### Claim 75 (depends on 74)

The nucleotide sequence of claim 74, wherein the nucleotide sequence further comprises a sequence encoding a gene encoding the transcriptional activator protein, wherein said gene is inserted into a constitutively expressed gene locus (e.g., ROSA26).

### Claim 76 (depends on 75)

The nucleotide sequence of claim 75, wherein expression of the gene encoding the transcriptional activator protein is inducible.

### Claim 77 (depends on 74, 75, 76)

The nucleotide sequence of any one of claims 74 to 76, wherein said inducible promoter is or comprises a tetracycline-response element (TRE) and wherein said transcriptional activator is a tetracycline transactivator (e.g., rtTA or rtTA2).

### Claim 78 (depends on 74, 75, 76, 77)

The nucleotide sequence of any one of claims 74 to 77, wherein expression of the transcriptional activator is induced in the presence of tetracycline and/or doxycycline.

### Claim 79 (depends on 73, 74, 75, 76, 77, 78)

The nucleotide sequence of any one of claims 73 to 78, wherein said skin cell-specific promoter is or comprises keratin 14 (K14), Krt6a, or K5.

### Claim 80 (depends on 73, 74, 75, 76, 77, 78, 79)

The nucleotide sequence of any one of claims 73 to 79, wherein said upstream cleavable sequence is or comprises a loxP site (i.e., Lox-STOP-Lox site).

### Claim 81 (depends on 73, 74, 75, 76, 77, 78, 79, 80)

The nucleotide sequence of any one of claims 73 to 80, wherein said upstream cleavable sequence is or comprises a flippase recognition target (FRT) site.

### Claim 82 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81)

The nucleotide sequence of any one of claims 73 to 81, wherein said recombinase is or comprises a Cre recombinase or a flippase recombinase.

### Claim 83 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The nucleotide sequence of any one of claims 73 to 82, wherein said recombinase is fused to a receptor, such as an estrogen receptor (e.g., ERT2).

### Claim 84 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The nucleotide sequence of any one of claims 73 to 83, wherein activation of the recombinase is induced in the presence of tamoxifen.

### Claim 85 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The nucleotide sequence of any one of claims 73 to 84, wherein said cassette further comprises a third downstream sequence encoding a gene encoding a fluorescent marker or protein (e.g., green fluorescent protein [GFP]).

### Claim 86 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The nucleotide sequence of any one of claims 73 to 85, wherein said genetic safe-harbour site is or comprises the Col1a1 gene locus.

### Claim 87 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The nucleotide sequence of any one of claims 73 to 86, wherein the sequence encoding the short hairpin RNA (shRNA) targeting Ptch1 comprises the sequence of any one of SEQ ID NOs: 1-10.

### Claim 88 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The nucleotide sequence of any one of claims 73 to 87, wherein the sequence encoding the short hairpin RNA (shRNA) targeting p53 comprises the sequence of SEQ ID NO: 11.

### Claim 89

A short hairpin RNA targeting Ptch1, said shRNA being encoded by a sequence having at least 50, 60, 70, 80, 90, 95, or 99% identity to the sequence of any one of SEQ ID NOs: 1-10.

### Claim 90

A short hairpin RNA targeting Ptch1, said shRNA being encoded by the sequence of any one of SEQ ID NOs: 1-10.

### Claim 91

A short hairpin RNA targeting Ptch1, said shRNA targeting a portion or region on SEQ ID NO: 12 that is at least 50, 60, 70, 80, 90, 95, 99%, or 100% identical to one or more of:
(xi) Nucleobases 2776-2796 of SEQ ID NO: 12;
(xii) Nucleobases 3601-3621 of SEQ ID NO: 12;
(xiii) Nucleobases 442-462 of SEQ ID NO: 12;
(xiv) Nucleobases 443-463 of SEQ ID NO: 12;
(xv) Nucleobases 2526-2546 of SEQ ID NO: 12;
(xvi) Nucleobases 1912-1933 of SEQ ID NO: 12;
(xvii) Nucleobases 964-986 of SEQ ID NO: 12;
(xviii) Nucleobases 2859-2880 of SEQ ID NO: 12;
(xix) Nucleobases 2864-2884 of SEQ ID NO: 12; and
(xx) Nucleobases 824-844 of SEQ ID NO: 12.

### Claim 92 (depends on 89, 90, 91)

A composition or kit comprising one or more of the shRNAs as defined in any one of claims 89 to 91.

### Claim 93 (depends on 89, 90, 91, 92)

The shRNA of any one of claims 89-91 or the composition or kit of claim 92 for use in inducing BCC in a non-human animal.

### Claim 94 (depends on 71, 72)

A non-human animal expressing the gene cassette or vector of claim 71 or 72.

### Claim 95 (depends on 71, 72)

A cell comprising or expressing the gene cassette or vector of claim 71 or 72.

### Claim 96

A genetically-modified non-human animal whose genome comprises:
an inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53.

### Claim 97 (depends on 96)

The genetically modified non-human animal of claim 96, wherein the inducible cassette is heterzogyously expressed.

### Claim 98 (depends on 97)

The genetically modified non-human animal of claim 97, wherein the inducible cassette is homozygously expressed.

### Claim 99

A cell comprising:
an inducible cassette inserted into a genetic safe harbour site, wherein said cassette comprises:
an upstream cleavable sequence that blocks expression of downstream sequences or genes;
a first downstream sequence encoding a short hairpin RNA (shRNA) targeting Ptch1; and
a second downstream sequence encoding a shRNA targeting p53.
